Novo Nordisk Aktie
| 39,18EUR | -0,93EUR | -2,31% |
WKN DE: A3EU6F / ISIN: DK0062498333
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 45 323 | 47 792 | 54 393 | 63 370 | 76 302 |
| Umsatz pro Mitarbeiter in Mio. EUR | 2,80 | 2,95 | 3,25 | 3,67 | 3,81 |
Bilanz (in Mio. DKK) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 65 809 | 85 595 | 108 194 | 139 646 | 160 897 |
| Summe Anlagevermögen | 79 113 | 108 913 | 133 063 | 174 840 | 304 898 |
| Summe Aktiva | 144 922 | 194 508 | 241 257 | 314 486 | 465 795 |
Bilanz (in Mio. DKK) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 81 597 | 123 762 | 157 771 | 207 925 | 322 309 |
| Summe Eigenkapital | 63 325 | 70 746 | 83 486 | 106 561 | 143 486 |
| Summe Passiva | 144 922 | 194 508 | 241 257 | 314 486 | 465 795 |
Adresse
| Novo Allé 1, 2880 Bagsværd | |
| Internet | http://www.novonordisk.com |
Management
|
Andreas Fibig
Independent Director |
|
Christina Law
Independent Director |
|
Douglas Langa
EVP & Head-North America Operations |
|
Elisabeth Dahl Christensen
Non-Independent Director |
|
Emil Kongshøj Larsen
Senior Vice President-Europe & Canada |
|
Gregory Miley
Head-Corporate Affairs |
|
Helge Lund
Chairman |
|
Henrik Ehlers Wulff
Executive Vice President-Product Supply |
|
Henrik Poulsen
Vice Chairman |
|
Irina Ivanischeva
Vice President & General Manager |
|
Jacob Martin Wiborg Rode
Head-Investor Relations |
|
Jane Buus Laursen
Corporate Vice President |
|
John F. McDonald
VP, Global Head-Business Development, M&A |
|
Karsten Munk Knudsen
Chief Financial Officer & Executive Vice President |
|
Kasim Kutay
Non-Independent Director |
|
Kristine Færch
Project Director-Data Science |
|
Laurence Debroux
Independent Director |
|
Liselotte Hyveled
Non-Independent Director & Chief Patient Officer |
|
Ludovic Helfgott
Executive VP-Product & Portfolio Strategy |
|
Martin Holst Lange
Chief Scientific Officer & Executive VP |
|
Martin W. MacKay
Independent Director |
|
Maziar Mike Doustdar
President & Chief Executive Officer |
|
Mette Bøjer Jensen
Non-Independent Director |
|
Mette Zacho
Vice President |
|
Robin Evers
Senior VP & Head-Global Regulatory Affairs |
|
Stephen Gough
Global Chief Medical Officer |
|
Sylvie Louise Grégoire
Independent Director |
|
Tania Sabroe
EVP-People, Organisation & Corporate Affairs |
|
Thilde Hummel Bogebjerg
Executive VP-Quality, IT & Environmental Affairs |
|
Thomas Rantzau
Non-Independent Director |
|
Tina Abild Olesen
Senior Vice President-Global Diabetes Franchise |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.